


REMARKS

Claims 4-12 are pending.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF



Jason D. Voight  
Reg. No. 42,205

1101 Connecticut Ave., N.W.  
Washington, D.C. 20036  
(202)659-0100

JDV/kas

2014-03-17 10:43:17

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please cancel claims 1-3.

Please add the following claims.

7. (new) A method for treating or preventing a fibrotic disorder, said method comprising administering an effective amount of an endothelin inhibitor to a mammal.


8. (new) The method of claim 7, wherein the disorder is a fibrotic disorder of the liver.

9. (new) The method of claim 7, wherein the disorder is fibrosis or cirrhosis.

10. (new) The method of claim 7, wherein the endothelin inhibitor is an endothelin receptor antagonist.

11. (new) The method of claim 7, wherein the endothelin inhibitor is a specific ETA receptor antagonist.

12. (new) The method of claim 7, wherein the endothelin inhibitor is a compound of formula I



where

R<sup>1</sup> and R<sup>2</sup> independently are C<sub>1</sub>-C<sub>2</sub>-alkyl or C<sub>1</sub>-C<sub>2</sub>-alkoxy,

R<sup>3</sup> is C<sub>1</sub>-C<sub>2</sub>-alkyl which may carry a phenyl which may carry up to 2 identical or different C<sub>1</sub>-C<sub>2</sub>-alkoxy radicals, and

Z is oxygen or a single bond.

**COPY OF ALL CLAIMS**

4. Pharmaceutical composition for prophylaxis or treatment of fibrotic disorders comprising as effective compound an endothelin inhibitor.

5. Pharmaceutical compositions according to claim 4 where the endothelin inhibitor is an endothelin receptor antagonist.

6. Pharmaceutical compositions according to claim 4 where the endothelin inhibitor is a specific ETA receptor antagonist.

7. (new) A method for treating or preventing a fibrotic disorder, said method comprising administering an effective amount of an endothelin inhibitor to a mammal.


8. (new) The method of claim 7, wherein the disorder is a fibrotic disorder of the liver.

9. (new) The method of claim 7, wherein the disorder is fibrosis or cirrhosis.

10. (new) The method of claim 7, wherein the endothelin inhibitor is an endothelin receptor antagonist.

11. (new) The method of claim 7, wherein the endothelin inhibitor is a specific ETA receptor antagonist.

12. (new) The method of claim 7, wherein the endothelin inhibitor is a compound of formula I



where

R<sup>1</sup> and R<sup>2</sup> independently are C<sub>1</sub>-C<sub>2</sub>-alkyl or C<sub>1</sub>-C<sub>2</sub>-alkoxy,

A1

R<sup>3</sup> is C<sub>1</sub>-C<sub>2</sub>-alkyl which may carry a phenyl which may carry up to 2 identical or different

C<sub>1</sub>-C<sub>2</sub>-alkoxy radicals, and

Z is oxygen or a single bond.

---

2017-01-14 10:43:33